Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. Pascal is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “PAS”.
280 7th Avenue East, Vancouver, BC V5T 0B4, CA
UPLOAD NEW PRESS RELEASE (log in required)
Log in to upload press releases
PASCAL BIOSCIENCES Q&A
If you have any questions about Pascal Biosciences or any of their products, please post them here.